Study S002530

A Double-Blind, Randomized, Multi-Center, Dose-Ranging, Phase 2 Study of the Efficacy and Safety of ALV-100 Versus Placebo for Maintenance of Weight Loss in Patients Previously Treated With Incretin-Based Therapies

ClinicalTrials.gov record

Registration

Registration: NCT07837973
Acronym: PRESERVE
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: RECRUITING
Enrollment: 220
Start: 2026-08-10
Primary completion: 2027-08-24
Lead sponsor: Alveus Therapeutics, Inc.
Conditions: Overweight , Obesity; Adults
Interventions: DRUG:ALV-100; DRUG:Placebo
Results posted: FALSE

Registered primary outcomes

Dose response of ALV-100 as assessed by maintenance of weight loss [24 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.